This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
📄
About this document — a plain-language guide
What it is. The Clinical Development Plan — the strategic roadmap of studies from first-in-human to registration and beyond.
Why it exists. The CDP is the scientific strategy: which studies, in what sequence, answer the questions needed for approval and labeling. It ties the individual trials into a coherent program.
How it is produced here. It is a program-management document: the planning, budgeting, and governance wrapper around the science — how the whole development program is run as a project.
Program-level strategic plan for GLPI-103: target product profile, unmet need, scientific rationale, competitor landscape, and the Phase 1–3 clinical development and regulatory strategy. Quantitative parameters are aligned to the canonical reconciliation in (); where the original plan was revised for cost/realism, this is noted (see PM-003 budget rationale).
Migrated to the structured dossier; phase sizes aligned to REF-002 (SAD 40 / MAD 40 / Ph2 240 / Ph3 900 planned, 900 randomized to target)
Indications under development: (1) Type 2 Diabetes Mellitus (primary); (2) Obesity; (3) Cardiometabolic disease; (4) Heart Failure with preserved Ejection Fraction (future lifecycle management).
Executive Summary
GLPI-103 is a first-in-class dual agonist of the GLP-1 receptor and the Apelin (APJ) receptor. While GLP-1 receptor agonists deliver meaningful glycaemic, weight, and cardiovascular benefit, substantial residual cardiometabolic and heart-failure risk persists in T2DM. Activation of the Apelin/APJ pathway is associated with improved insulin sensitivity, enhanced endothelial function, improved cardiac contractility, reduced inflammation, and favourable metabolic effects. GLPI-103 is designed to deliver superior glycaemic control, greater weight reduction, and improved cardiometabolic outcomes — with potential heart-failure risk reduction — beyond GLP-1 agonism alone.
5.2 Development questions — does dual GLP-1/APJ agonism deliver glycaemic superiority over a guideline comparator with acceptable tolerability, and does it improve cardiometabolic biomarkers?
GLPI103-102 (MAD) — multiple ascending dose, 40 overweight/obese adults with T2DM or prediabetes, up to 12 weeks (4 dose cohorts × 10). Results: mean HbA1c −0.8%, weight −3.1 kg.
7. Phase 2 Program Summary
GLPI103-201 — randomized, double-blind, placebo-controlled dose-finding (PoC) in T2DM on metformin; 240 subjects (Placebo / Low / Medium / High × 60); 24 weeks; primary endpoint HbA1c CFB.
Group
HbA1c change
Weight change
Placebo
−0.2%
−0.5 kg
Low
−1.0%
—
Medium
−1.4%
—
High
−1.8%
−8.2 kg
Cardiometabolic biomarkers (hsCRP, NT-proBNP, HOMA-IR) improved; common TEAEs nausea/vomiting/diarrhoea; no unexpected safety signals.
8. Phase 3 Development Plan
GLPI103-301 — randomized, double-blind, double-dummy, active-controlled; adults with T2DM inadequately controlled on metformin. 900 randomized to target (≈300/arm).
Arms: A GLPI-103 IV (1→2→4 mg); B GLPI-103 Oral (2→4→8 mg); C oral semaglutide (3→7→14 mg).
Primary endpoint: HbA1c change from baseline at Week 52 (superiority vs semaglutide).
Statistical framework: primary MMRM (estimand-aligned), hierarchical (fixed-sequence) multiplicity, α=0.05, power 90% (SAP-301; executed analyses in SAR-301).
9. Regulatory & Commercialization Strategy
Target submissions: FDA NDA, EMA MAA, MFDS NDA, PMDA NDA. Planned filing window Q4 2031. Regional plans and labeling: Module 1 (regulatory/m1/).
10. Clinical Operations Plan
Operational execution (monitoring, data management, randomization/IWRS, safety, pharmacy/IMP, laboratory) is detailed in the Trial Master File (tmf/); program governance/timeline/budget/vendor in PM-001–006.